RS56844B1 - Retrovirusni vektori sa modifikovanim polipurinskim nizom - Google Patents
Retrovirusni vektori sa modifikovanim polipurinskim nizomInfo
- Publication number
- RS56844B1 RS56844B1 RS20180107A RSP20180107A RS56844B1 RS 56844 B1 RS56844 B1 RS 56844B1 RS 20180107 A RS20180107 A RS 20180107A RS P20180107 A RSP20180107 A RS P20180107A RS 56844 B1 RS56844 B1 RS 56844B1
- Authority
- RS
- Serbia
- Prior art keywords
- vector
- integration
- sequence
- retroviral
- defective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polyurethanes Or Polyureas (AREA)
- Artificial Filaments (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US711807P | 2007-12-11 | 2007-12-11 | |
| PCT/US2008/086409 WO2009076524A2 (en) | 2007-12-11 | 2008-12-11 | Polypurine tract modified retroviral vectors |
| EP08859393.4A EP2222861B1 (en) | 2007-12-11 | 2008-12-11 | Polypurine tract modified retroviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS56844B1 true RS56844B1 (sr) | 2018-04-30 |
Family
ID=40756119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20180107A RS56844B1 (sr) | 2007-12-11 | 2008-12-11 | Retrovirusni vektori sa modifikovanim polipurinskim nizom |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9796987B2 (enExample) |
| EP (2) | EP2222861B1 (enExample) |
| JP (2) | JP5749014B2 (enExample) |
| CY (1) | CY1119905T1 (enExample) |
| DK (1) | DK2222861T3 (enExample) |
| ES (1) | ES2664988T3 (enExample) |
| HR (1) | HRP20180184T1 (enExample) |
| HU (1) | HUE036103T2 (enExample) |
| LT (1) | LT2222861T (enExample) |
| NO (1) | NO2222861T3 (enExample) |
| PL (1) | PL2222861T3 (enExample) |
| PT (1) | PT2222861T (enExample) |
| RS (1) | RS56844B1 (enExample) |
| SI (1) | SI2222861T1 (enExample) |
| TR (1) | TR201802323T4 (enExample) |
| WO (1) | WO2009076524A2 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006252406B2 (en) | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| SG173337A1 (en) | 2006-07-21 | 2011-08-29 | California Inst Of Techn | Targeted gene delivery for dendritic cell vaccination |
| RS56844B1 (sr) | 2007-12-11 | 2018-04-30 | Univ North Carolina Chapel Hill | Retrovirusni vektori sa modifikovanim polipurinskim nizom |
| WO2011011584A1 (en) * | 2009-07-24 | 2011-01-27 | Immune Design Corp | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
| SG192759A1 (en) | 2011-02-15 | 2013-09-30 | Immune Design Corp | Methods for enhancing immunogen specific immune responses by vectored vaccines |
| WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| EP2831095B1 (en) | 2012-03-30 | 2018-11-28 | Immune Design Corp. | Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign |
| US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
| LT2850431T (lt) | 2012-05-16 | 2018-06-25 | Immune Design Corp. | Vakcinos, skirtos hsv-2 |
| CA2939093A1 (en) | 2014-02-14 | 2015-08-20 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
| KR20170032373A (ko) | 2014-07-15 | 2017-03-22 | 이뮨 디자인 코포레이션 | Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법 |
| KR101607282B1 (ko) | 2014-12-18 | 2016-03-29 | 충남대학교산학협력단 | 유리형 산화환원조절단백-1 및 이를 함유하는 항염증 약학조성물 |
| JP6734283B2 (ja) | 2015-01-21 | 2020-08-05 | フレッド ハッチンソン キャンサー リサーチ センター | 遺伝子治療用ポイントオブケア及び／又はポータブルプラットフォーム |
| US11078495B2 (en) | 2015-10-15 | 2021-08-03 | The University Of North Carolina At Chapel Hill | Methods and compositions for integration defective lentiviral vectors |
| KR20180108567A (ko) | 2015-10-22 | 2018-10-04 | 주노 테라퓨틱스 게엠베하 | 형질도입을 위한 방법, 키트, 제제 및 장치 |
| CA3004132A1 (en) | 2015-11-09 | 2017-05-18 | Immune Design Corp. | A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids |
| MX2018005467A (es) | 2015-11-09 | 2018-12-11 | Immune Design Corp | Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas. |
| MX2018010061A (es) | 2016-02-23 | 2019-07-04 | Immune Design Corp | Preparaciones de vectores retrovirales de genomas multiples, y metodos y sistemas para producir y usar las mismas. |
| EP3443000B1 (en) | 2016-04-15 | 2025-11-12 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| KR102824067B1 (ko) | 2016-04-15 | 2025-06-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| US11421287B2 (en) | 2016-07-29 | 2022-08-23 | Juno Therapeutics, Inc. | Methods for assessing the presence or absence of replication competent virus |
| CN110249046A (zh) | 2016-12-05 | 2019-09-17 | 朱诺治疗学股份有限公司 | 用于过继细胞疗法的工程化细胞的产生 |
| LT3596116T (lt) | 2017-03-16 | 2023-11-10 | Alpine Immune Sciences, Inc. | Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai |
| CN110809581A (zh) | 2017-03-16 | 2020-02-18 | 高山免疫科学股份有限公司 | Pd-l2变体免疫调节蛋白及其用途 |
| CA3054068A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| MX2020000900A (es) | 2017-07-29 | 2021-01-08 | Juno Therapeutics Inc | Reactivos para expandir celulas que expresan receptores recombinantes. |
| CA3070579A1 (en) | 2017-08-09 | 2019-02-14 | Juno Therapeutics, Inc. | Methods for producing genetically engineered cell compositions and related compositions |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| MX2020004540A (es) | 2017-10-18 | 2020-08-03 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados. |
| WO2019089855A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| JP7258899B2 (ja) | 2017-11-01 | 2023-04-17 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞組成物を作製するための方法 |
| KR102833956B1 (ko) | 2017-12-08 | 2025-07-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포를 배양하기 위한 무혈청 배지 제형 및 이의 사용 방법 |
| EP3735417A1 (en) | 2018-01-03 | 2020-11-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| EP3746569A1 (en) | 2018-01-31 | 2020-12-09 | Juno Therapeutics, Inc. | Methods and reagents for assessing the presence or absence of replication competent virus |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| CN113544144A (zh) | 2018-09-19 | 2021-10-22 | 高山免疫科学股份有限公司 | 变体cd80融合蛋白和相关构建体的方法和用途 |
| AU2019372331A1 (en) | 2018-11-01 | 2021-05-27 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| CA3120118A1 (en) | 2018-11-16 | 2020-05-22 | Juno Therapeutics, Inc. | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| CN113727998A (zh) | 2018-11-30 | 2021-11-30 | 高山免疫科学股份有限公司 | Cd86变体免疫调节蛋白及其用途 |
| IL283298B2 (en) | 2018-11-30 | 2025-03-01 | Juno Therapeutics Inc | Methods for dosing and treating B-cell malignancies with adoptive cell therapy |
| WO2020113194A2 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| AU2020257238A1 (en) | 2019-04-17 | 2021-12-02 | Alpine Immune Sciences, Inc. | Methods and uses of variant ICOS Ligand (ICOSL) fusion proteins |
| AU2020287882A1 (en) | 2019-06-07 | 2022-01-20 | Juno Therapeutics, Inc. | Automated T cell culture |
| MA56206A (fr) | 2019-06-12 | 2022-04-20 | Juno Therapeutics Inc | Combinaison thérapeutique d'une thérapie cytotoxique à médiation cellulaire et d'un inhibiteur d'une protéine de la famille bcl2 pro-survie |
| JP2022545467A (ja) | 2019-08-22 | 2022-10-27 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法 |
| EP4055383A1 (en) | 2019-11-05 | 2022-09-14 | Juno Therapeutics, Inc. | Methods of determining attributes of therapeutic t cell compositions |
| AU2020395318A1 (en) | 2019-12-06 | 2022-06-09 | Juno Therapeutics, Inc. | Methods related to toxicity and response associated with cell therapy for treating B cell malignancies |
| MX2022009041A (es) | 2020-01-24 | 2022-10-07 | Juno Therapeutics Inc | Metodos de dosificacion y tratamiento de linfoma folicular y linfoma de zona marginal en terapia celular adoptiva. |
| KR20220146480A (ko) | 2020-01-28 | 2022-11-01 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｔ 세포 형질도입 방법 |
| KR20230009386A (ko) | 2020-04-10 | 2023-01-17 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도 |
| CN115812077A (zh) | 2020-05-08 | 2023-03-17 | 高山免疫科学股份有限公司 | April和baff抑制性免疫调节蛋白及其使用方法 |
| JP7727662B2 (ja) | 2020-05-13 | 2025-08-21 | ジュノー セラピューティクス インコーポレイテッド | 臨床応答に関連する特徴量の特定方法およびその使用 |
| CA3197730A1 (en) | 2020-10-15 | 2022-04-21 | F. Hoffman-La Roche Ag | Nucleic acid constructs for va rna transcription |
| WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
| CA3210581A1 (en) | 2021-03-22 | 2022-09-29 | Neil HAIG | Methods of determining potency of a therapeutic cell composition |
| AU2022244229A1 (en) | 2021-03-22 | 2023-09-14 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
| KR20240005700A (ko) | 2021-03-29 | 2024-01-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | 체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법 |
| WO2022236335A1 (en) | 2021-05-07 | 2022-11-10 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
| US20250059560A1 (en) | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
| WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| JP2025521543A (ja) | 2022-06-22 | 2025-07-10 | ジュノー セラピューティクス インコーポレイテッド | Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法 |
| EP4598557A2 (en) | 2022-10-04 | 2025-08-13 | Alpine Immune Sciences, Inc. | Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases |
| WO2024220588A1 (en) | 2023-04-18 | 2024-10-24 | Juno Therapeutics, Inc. | Cytotoxicity assay for assessing potency of therapeutic cell compositions |
| WO2024226858A1 (en) | 2023-04-26 | 2024-10-31 | Juno Therapeutics, Inc. | Methods for viral vector manufacturing |
| WO2024243365A2 (en) | 2023-05-23 | 2024-11-28 | Juno Therapeutics, Inc. | Activation markers of t cells and method for assessing t cell activation |
| WO2024263991A2 (en) * | 2023-06-22 | 2024-12-26 | Arc Research Institute | Methods and compositions for integration deficient viral vectors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861161A (en) | 1994-09-07 | 1999-01-19 | Universite De Montreal | Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions |
| CN100390291C (zh) | 1995-11-28 | 2008-05-28 | 约翰斯·霍普金斯大学医学院 | 条件复制型病毒载体及其用法 |
| AU1100201A (en) | 1999-10-28 | 2001-05-08 | Board Of Trustees Of The Leland Stanford Junior University | Methods of in vivo gene transfer using a sleeping beauty transposon system |
| US6673567B2 (en) | 2000-03-23 | 2004-01-06 | E. I. Du Pont De Nemours And Company | Method of determination of gene function |
| US20030003565A1 (en) * | 2000-11-27 | 2003-01-02 | Dubensky Thomas W. | Functional lentiviral vector from an MLV-based backbone |
| EP1534847B1 (en) | 2002-09-03 | 2015-10-28 | Oxford Biomedica (UK) Limited | Retroviral vector and stable packaging cell lines |
| US7220578B2 (en) | 2002-11-27 | 2007-05-22 | Tal Kafri | Single LTR lentivirus vector |
| WO2005023313A1 (en) * | 2003-09-09 | 2005-03-17 | Virxsys Corporation | Lentivirus vector-based approaches for generating an immune response to hiv humans |
| GB0325379D0 (en) | 2003-10-30 | 2003-12-03 | Oxford Biomedica Ltd | Vectors |
| WO2005056057A1 (en) * | 2003-12-04 | 2005-06-23 | Childrens Hospital Los Angeles Research Institute | Minimal lentiviral vector system |
| US20070048285A1 (en) * | 2005-08-24 | 2007-03-01 | Christopher Baum | Self-inactivating retroviral vector |
| EP1757703A3 (en) | 2005-08-24 | 2007-12-05 | Medizinische Hochschule Hannover | Self-inactivating retroviral vector |
| RS56844B1 (sr) | 2007-12-11 | 2018-04-30 | Univ North Carolina Chapel Hill | Retrovirusni vektori sa modifikovanim polipurinskim nizom |
-
2008
- 2008-12-11 RS RS20180107A patent/RS56844B1/sr unknown
- 2008-12-11 WO PCT/US2008/086409 patent/WO2009076524A2/en not_active Ceased
- 2008-12-11 ES ES08859393.4T patent/ES2664988T3/es active Active
- 2008-12-11 PL PL08859393T patent/PL2222861T3/pl unknown
- 2008-12-11 NO NO08859393A patent/NO2222861T3/no unknown
- 2008-12-11 HU HUE08859393A patent/HUE036103T2/hu unknown
- 2008-12-11 HR HRP20180184TT patent/HRP20180184T1/hr unknown
- 2008-12-11 PT PT88593934T patent/PT2222861T/pt unknown
- 2008-12-11 TR TR2018/02323T patent/TR201802323T4/tr unknown
- 2008-12-11 SI SI200831929T patent/SI2222861T1/en unknown
- 2008-12-11 US US12/747,076 patent/US9796987B2/en active Active
- 2008-12-11 LT LTEP08859393.4T patent/LT2222861T/lt unknown
- 2008-12-11 EP EP08859393.4A patent/EP2222861B1/en active Active
- 2008-12-11 JP JP2010538155A patent/JP5749014B2/ja not_active Expired - Fee Related
- 2008-12-11 DK DK08859393.4T patent/DK2222861T3/en active
- 2008-12-11 EP EP17204678.1A patent/EP3342872A1/en not_active Withdrawn
-
2015
- 2015-01-28 JP JP2015013974A patent/JP6001702B2/ja not_active Expired - Fee Related
-
2017
- 2017-10-23 US US15/790,530 patent/US10017785B2/en active Active
-
2018
- 2018-02-09 CY CY20181100167T patent/CY1119905T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1119905T1 (el) | 2018-06-27 |
| SI2222861T1 (en) | 2018-04-30 |
| JP2011505835A (ja) | 2011-03-03 |
| TR201802323T4 (tr) | 2018-03-21 |
| NO2222861T3 (enExample) | 2018-05-05 |
| HUE036103T2 (hu) | 2018-06-28 |
| EP2222861B1 (en) | 2017-12-06 |
| EP3342872A1 (en) | 2018-07-04 |
| JP5749014B2 (ja) | 2015-07-15 |
| LT2222861T (lt) | 2018-03-26 |
| DK2222861T3 (en) | 2018-02-05 |
| US10017785B2 (en) | 2018-07-10 |
| EP2222861A2 (en) | 2010-09-01 |
| JP6001702B2 (ja) | 2016-10-05 |
| US20180119170A1 (en) | 2018-05-03 |
| US9796987B2 (en) | 2017-10-24 |
| EP2222861A4 (en) | 2011-12-28 |
| US20100323403A1 (en) | 2010-12-23 |
| JP2015119715A (ja) | 2015-07-02 |
| ES2664988T3 (es) | 2018-04-24 |
| WO2009076524A3 (en) | 2009-09-11 |
| PT2222861T (pt) | 2018-02-16 |
| PL2222861T3 (pl) | 2018-04-30 |
| HRP20180184T1 (hr) | 2018-04-06 |
| WO2009076524A2 (en) | 2009-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10017785B2 (en) | Polypurine tract modified retroviral vectors | |
| KR102091957B1 (ko) | 레트로바이러스 생산을 위한 안정한 세포주 | |
| Pluta et al. | Use of HIV as a gene transfer vector | |
| AU2016359838B2 (en) | Transient transfection method for retroviral production | |
| CN109415415B (zh) | 用于衣壳化基因组工程系统的颗粒 | |
| US20120115227A1 (en) | Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements | |
| GB2538324A (en) | Packaging cell line for retroviral production | |
| GB2538321A (en) | Artificial chromosome for retroviral production | |
| Schambach et al. | Retroviral vectors for cell and gene therapy | |
| van Heuvel | Optimization of retroviral packaging cells for scale-up of vector production | |
| Durosa et al. | g-RETROVIRUS-AND LENTIVIRUS-DERIVED VECTORS FOR GENE TRANSFER AND THERAPY | |
| WO2025213067A2 (en) | Methods and compositions for increased expression of integration deficient viral vectors | |
| WO2024263991A2 (en) | Methods and compositions for integration deficient viral vectors | |
| Binder et al. | Lentivirus vectors | |
| Duros et al. | γ-RETROVIRUS-AND LENTIVIRUS-DERIVED VECTORS FOR GENE TRANSFER AND THERAPY | |
| Heuvel | Optimization of retroviral packaging cells for scale-up of vector production | |
| GB2544891A (en) | Transient transfection method for retroviral production |